arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cytosorbents Corp

CTSO
$0.37 ▼ -0.02 (-4.77%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
79 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytosorbents Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $23.2M
Dividend Yield
Revenue Growth 1.6%
Op. Margin -34.3%
ROIC -12.6%
FCF / Share $-0.02
Trailing P/E
Price / Book 10.6x
FCF Yield
Debt / Equity 7.73
info Valuation on last close. End-of-day price, Aug 7, 2026.

79-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.86M
↑ +1.6%
Net Income Profit after all expenses
$-5.13M
↓ -246.9%
Operating Margin Operating profit as % of sales
-34.3%
↓ -13.8% 6th
FCF / Share Free cash flow per share
$-0.02
↑ +67.2%
Long-Term Debt Long-term obligations
$16.96M
↑ +1.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
6
Financial Health
21
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 29 years · 79 quarters